- Home
- HROW vs TNDM Comparison
HROW vs TNDM Comparison
Compare HROW & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- TNDM
- Stock Information
- Founded
- HROW 1998
- TNDM 2006
- Country
- HROW United States
- TNDM United States
- Employees
- HROW N/A
- TNDM N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- TNDM Medical/Dental Instruments
- Sector
- HROW Health Care
- TNDM Health Care
- Exchange
- HROW Nasdaq
- TNDM Nasdaq
- Market Cap
- HROW 1.1B
- TNDM 1.1B
- IPO Year
- HROW N/A
- TNDM 2013
- Fundamental
- Price
- HROW $34.93
- TNDM $15.59
- Analyst Decision
- HROW Strong Buy
- TNDM Buy
- Analyst Count
- HROW 7
- TNDM 13
- Target Price
- HROW $61.83
- TNDM $32.15
- AVG Volume (30 Days)
- HROW 368.3K
- TNDM 1.6M
- Earning Date
- HROW 08-06-2025
- TNDM 08-06-2025
- Dividend Yield
- HROW N/A
- TNDM N/A
- EPS Growth
- HROW N/A
- TNDM N/A
- EPS
- HROW N/A
- TNDM N/A
- Revenue
- HROW $212,858,000.00
- TNDM $982,951,000.00
- Revenue This Year
- HROW $44.89
- TNDM $8.91
- Revenue Next Year
- HROW $38.22
- TNDM $11.04
- P/E Ratio
- HROW N/A
- TNDM N/A
- Revenue Growth
- HROW 53.49
- TNDM 27.65
- 52 Week Low
- HROW $20.85
- TNDM $15.17
- 52 Week High
- HROW $59.23
- TNDM $48.24
- Technical
- Relative Strength Index (RSI)
- HROW 70.24
- TNDM 27.20
- Support Level
- HROW $30.81
- TNDM $15.17
- Resistance Level
- HROW $33.27
- TNDM $17.12
- Average True Range (ATR)
- HROW 1.37
- TNDM 0.99
- MACD
- HROW 0.09
- TNDM -0.31
- Stochastic Oscillator
- HROW 88.78
- TNDM 6.99
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.